NASDAQ · ARDX
Ardelyx, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ARDX: Nov 03, 2026
Ardelyx, Inc. Common Stock is expected to report earnings on 11/03/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.03. The reported EPS for the same quarter last year was $0.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.03 | $0.01 | $-0.06 | 5 |
| Dec 2026 | $0.03 | $0.06 | $0.01 | 5 |
| Mar 2027 | $-0.05 | $-0.01 | $-0.09 | 3 |
| Jun 2027 | $0.01 | $0.03 | $0.00 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · MarketBeat · The Motley Fool- RTTNews · Oct 12, 10:20 AM EDTArdelyx Reports Reduced Healthcare Utilization Following IBSRELA Initiation At ACG 2026(RTTNews) – Ardelyx, Inc. (ARDX), a commercial-stage biopharmaceutical company, announced real-world data showing reduced gastrointestinal-related healthcare resource utilization among adults with irritable bowel syndrome with constipation (IBS-C) following initiation of IBSRELA
- Zacks · Oct 9, 5:12 AM EDTNew Strong Sell Stocks for October 9thACH, ARDX and DPRO have been added to the Zacks Rank #5 (Strong Sell) List on October 9th, 2026.
- Zacks · Oct 7, 2:23 AM EDTNew Strong Sell Stocks for October 7thARDX, LUV and COLL have been added to the Zacks Rank #5 (Strong Sell) List on October 7th, 2026.
- MarketBeat · Sep 21, 4:02 AM EDTArdelyx Targets $500M Revenue This Year, Profitability by 20273 mid-caps under $20 that Wall Street lovesArdelyx (NASDAQ:ARDX) expects to generate close to $500 million in revenue this year and reach profitability in 2027, supported by continued growth of its IBS-C treatment IBSRELA and hyperphosphatemia treatment XPHOZAH, executives said a
- The Motley Fool · Aug 13, 8:44 PM EDTArdelyx (ARDX) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Aug 7, 4:34 AM EDTNew Strong Sell Stocks for August 7thARDX, ARDT and GPRE have been added to the Zacks Rank #5 (Strong Sell) List on August 7th, 2026.
- Zacks · Aug 6, 7:10 PM EDTArdelyx (ARDX) Reports Q2 Loss, Lags Revenue EstimatesArdelyx (ARDX) delivered earnings and revenue surprises of -40.00% and -2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 6, 7:00 PM EDTCompared to Estimates, Ardelyx (ARDX) Q2 Earnings: A Look at Key MetricsWhile the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- MarketBeat · Aug 6, 6:04 PM EDTArdelyx Q2 Earnings Call Highlights3 mid-caps under $20 that Wall Street lovesArdelyx (NASDAQ:ARDX) reported second-quarter product revenue of $118 million, up 31% from a year earlier and representing the company’s largest quarterly revenue total to date. The company lowered its 2026 revenue outlook for IBSRELA wh
- Zacks · Aug 3, 7:45 AM EDTIndivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat EstimatesIndivior Pharmaceuticals Inc. (INDV) delivered earnings and revenue surprises of +18.56% and +11.36%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 30, 10:00 AM EDTWill Ardelyx (ARDX) Report Negative Earnings Next Week? What You Should KnowArdelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Jul 29, 5:29 AM EDTNew Strong Sell Stocks for July 29thARDX, BDORY and AXSM have been added to the Zacks Rank #5 (Strong Sell) List on July 29, 2026.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Ardelyx, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.